The bacterium that causes Lyme disease is a master of disguise, changing its appearance to evade the immune system as it moves from the ticks that carry it to humans or animals.
Academic rigour, journalistic flair
Articles on Vaccine development
Displaying 1 - 20 of 70 articles
Annual flu vaccines are in a constant race against a rapidly mutating virus that may one day cause the next pandemic. A one-time vaccine protecting against all variants could give humanity a leg up.
An effective nasal vaccine could stop the virus that causes COVID-19 right at its point of entry. But devising one that works has been a challenge for researchers.
Using a Nobel Prize-winning technique called cryo-EM, researchers were able to identify potential areas on the hepatitis C virus that a vaccine could target.
Canadian scientists have made significant contributions during the pandemic response, including vital roles in developing COVID-19 vaccines. But underfunding puts the future of science in Canada at risk.
New boosters protect against the original COVID strain as well as Omicron. In future, we might see variant-proof vaccines or those delivered in the nose or mouth.
An inhaled COVID-19 vaccine would go directly to where the body would use it: the mucosal surface of the airways. This could mean less waste and more benefit, lower costs and reduced side-effects.
A new network of public clinical trials institutes is urgently needed to replenish the empty pipeline for new antibiotics.
Various strategies are being pursued to boost worldwide vaccine coverage.
It sounds too good to be true, a vaccine that can protect against future virus variants. But governments around the world are keen to learn more.
Increasing skills and the availability of raw materials would be a bigger boost for vaccine production right now.
Skyrocketing demand coupled with shortages of vital components is leading to bottlenecks in the supply chain of Pfizer’s and other mRNA vaccines.
The R21 vaccine protected three-quarters of children against malaria in trials.
We have two mRNA COVID-19 vaccines so far. But what else can this technology do?
The development of the COVID-19 vaccines is part of a vast system of public subsidies and universities, not corporate ambition.
You need a new shot every year because current flu vaccines provide limited and temporary protection. But researchers’ new strategy could mean a one-and-done influenza vaccine is on the way.
Tuberculosis is a global threat and a public health concern on a scale similar to COVID-19.
What normally takes decades has been achieved in 12 months, without cutting corners.
The coronavirus vaccine was developed faster than any vaccine in history. It took just 332 days from the first sequencing of the virus genome to the first vaccines given to the public.
We should applaud drug companies for developing COVID-19 vaccines in record time, but let’s not be under any illusion about the profits that are motivating them.
Job Board
-
Professor - Criminology
-
Research Assistant - Dewson Lab
-
Director, Business Development, AICF
-
Research Fellow in Human-Computer Interaction
-
Commissioning Editor, Health
Top contributors
-
Associate Professor of Viral Immunology, Department of Pathobiology, University of Guelph
-
Professor of Immunology and Associate Dean, Research and Graduate Studies, University of Guelph
-
Professor Emeritus of Health Policy and Management, York University, Canada
-
Associate professor, UNSW Sydney
-
Vice-Chancellor's Research Fellow, School of Health and Biomedical Sciences, RMIT University
-
Associate Professor, Infectious Diseases and Microbiology, The University of Queensland
-
Senior Project Manager, Jenner Institute, University of Oxford
-
Reader in Bioethics, University of Portsmouth
-
Professor Emerita of Biology, Indiana University
-
Ph.D. Student in Microbiology and Immunology, Vanderbilt Vaccine Center, Vanderbilt University
-
Ph.D. Candidate in Chemical & Physical Biology, Vanderbilt Vaccine Center, Vanderbilt University
-
Professor of Immunology, RMIT University
-
Infectious Diseases Specialist and Clinical Professor, University of Tasmania
-
Vaccine Knowledge Project Manager, University of Oxford
-
Associate Professor and ARC Future Fellow, The University of Western Australia
